Vergent Bioscience shares phase 2 data for VGT-309
Betsy Goodfellow | January 29, 2024 | News story | Research and Development | Oncology, VGT-309, Vergent Bioscience, lung cancer
Vergent Bioscience has announced new data from a phase 2 trial of VGT-309, the company’s investigational tumour-targeted fluorescent imaging agent. The data was presented at the 60th Annual Meeting of The Society of Thoracic Surgeons.
The data suggests that VGT-309 is effective at visualising primary and metastatic tumour tissue in lungs during surgery, helping surgeons to see difficult-to-find and previously undetected tumours in real time, and ensuring that all tumour tissue can be removed during minimally-invasive or robotic-assisted lung cancer surgery.
The phase 2 trial assessed the frequency that intraoperative molecular imaging (IMI) improved surgical outcomes in 40 patients with suspected or proven lung cancer who were eligible for surgery.
John Santini PhD, president and chief executive officer at Vergent Bioscience, commented: “The data presented today at STS 2024 suggest that VGT-309 could help support more confident and reliable removal of a wide breadth of cancers in the lung that would otherwise be missed during minimally invasive and robotic surgery. We look forward to the results from our ongoing, Phase 2 multi-center VISUALIZE study, which will provide further insight regarding the potential promising impact of VGT-309 for both cancer patients and surgeons.”
Sunil Singhal MD, lead investigator on the trial and chief of the division of thoracic surgery in the Perelman School of Medicine at the University of Pennsylvania, US, added: “Minimally invasive surgery has become standard of care for many cancer surgeries, but surgeons’ ability to see and remove all tumour tissue during these procedures is often hindered by poor visualisation. The data from the VGT-309 phase 2 efficacy study are encouraging, reinforcing the agent’s potential to help fill this critical gap.”
Betsy Goodfellow
Related Content
HUTCHMED completes enrolment in phase 3 trial for lung cancer
HUTCHMED has completed patient enrolment for the SANOVO phase 3 clinical trial, investigating the use …
Graphene-based biosensor to support new lung cancer screening test
HydroGraph, a Canadian producer of ultra-pure graphene, has announced a partnership with Hawkeye Bio and …
FDA approves diagnostic tool for MET-targeted lung cancer therapy
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay …
